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Abstract This year the most prestigious prize in medical
sciences, the Lasker Award, has been presented to the three
scientists who discovered the ubiquitin pathway: Aaron Ciechan-
over, Avram Hershko, and Alexander Varshavsky [Nature Med.
6 (2000) 1073^1081]. During a time when the scientific
community was focused on understanding how proteins were
synthesized, they intently pursued the novel idea that cells were
programmed to selectively destroy proteins. Their work led to the
identification of an elaborate system of protein degradation
targeting a myriad of cellular substrates. A small protein called
ubiquitin is at the center of this process. Although the ubiquitin
pathway was first described in the early 1980s, it has only more
recently advanced to the forefront of basic research as a
significant regulatory network within the cell. The field continues
to grow as new ubiquitination enzymes and novel functions of this
system are identified. Scientists are focused on elucidating the
mechanisms by which cells deploy the ubiquitin pathway to
control levels of selected proteins, such as cell cycle regulatory
proteins, transcription factors and signaling molecules. Acceler-
ated or decelerated rates of degradation of particular substrates
participate in the genesis of many human diseases. Thus,
understanding the mechanisms that confer specificity to the
ubiquitin system will allow the development of novel therapeutic
approaches to target aberrations in this pathway underlying
tumorigenesis and other human pathologies. ß 2001 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
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1. Introduction
Targeted protein degradation by the ubiquitin-proteasome
pathway plays a vital role in monitoring the abundance of
many short-lived regulatory proteins (reviewed in [2]). A poly-
ubiquitin chain is built onto one or multiple lysine residues of
a substrate to target it for capture and degradation by the 26S
proteasome. Then the proteolytic core of the proteasome pro-
cesses the ubiquitinated substrate into small peptides. The
conjugation of ubiquitin, a small (76 amino acid) heat-stable
polypeptide present in all eukaryotes, to a protein substrate is
executed by a series of well-de¢ned enzymatic reactions. The
three enzymes of this cascade were puri¢ed by a⁄nity chro-
matography of a crude reticulocyte extract over a ubiquitin-
Sepharose column. The enzymatic activity of the three eluates
(E1, E2, and E3) was characterized [3]. The ubiquitin-activat-
ing enzyme (E1) forms an ATP-dependent thioester bond with
ubiquitin and transfers it to one of many ubiquitin-conjugat-
ing enzymes (E2s or Ubcs). E2s form a thioester bond with
activated ubiquitin and transfer it to a substrate with the help
of one of many ubiquitin ligases (E3s or Ubls). Some ubiq-
uitin ligases such as the Hect proteins (homologous to E6-AP
C-terminus) can form a thioester bond with ubiquitin as an
intermediate in the transfer of ubiquitin from the E2 to the
substrate (reviewed in [4]). This tight ubiquitin regulatory cas-
cade is evolutionarily conserved from yeast to mammals.
Combinatorial interactions among di¡erent E2s and di¡erent
E3s generate a large number of speci¢c substrate targeting
complexes that regulate the stability of key proteins (Fig. 1).
The exact temporal and spatial destruction of substrates by
ubiquitin-mediated degradation is consistent with its task in
controlling cell division, transcription, cell signaling and de-
velopment.
Progression through the eukaryotic cell cycle is de¢ned by a
timed succession of distinct events (reviewed in [5]). A cell’s
regulatory machinery must guarantee completion of DNA
replication in the S (synthesis) phase before the chromosomes
are segregated into daughter cells at the end of the M (mito-
sis) phase. This periodic movement through the cell cycle is
orchestrated by programmed oscillations in the activity of a
family of serine/threonine protein kinases called cyclin-depen-
dent kinases (cdks). The activation of a cdk is dependent on
its association with a cyclin regulatory subunit ; inactivation is
regulated by its association with a cdk inhibitor (cki). Fur-
thermore, a ¢ne control by upstream cdk regulatory kinases
and phosphatases as well as by a transcriptional network me-
diates the £uctuation in cdk activity. Cdks and their regula-
tors are internal sensors of mitogenic and antimitogenic sig-
nals. Their rapid response to stimuli such as growth factors,
DNA damage, or cell^cell contact inhibition is critical for
controlled proliferation. Of particular interest for this review
is the rapid and temporal destruction of cellular regulatory
proteins by ubiquitin-dependent degradation to advance uni-
directional transitions through the cell cycle.
Two distinct ubiquitin conjugation pathways mediate cell
division by a¡ecting the following events: (1) transition
from G1 to S phase, (2) sister chromatid separation during
anaphase, and (3) exit from mitosis. The ¢rst event in G1/S,
initially characterized in Saccharomyces cerevisiae, requires
the E2 enzyme, Cdc34 (or Ubc3), and an E3 ligase complex
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termed SCFCdc4 (Skp-cullin-F-box protein) to activate DNA
replication. The two mitotic events require a large multi-pro-
tein E3 complex called the APC/C (anaphase promoting com-
plex/cyclosome) in combination with one of two distinct E2s
(Ubc10 or Ubc4). It regulates mitosis by a¡ecting chromo-
some and spindle dynamics and by regulating the activity of
mitotic cdks (reviewed in [5,6]). The focus of this review is the
role of the mammalian SCF ubiquitin ligases in the control of
the G1/S transition. Following a brief description of the con-
vergence of the cell cycle with the ubiquitin pathway is a
discussion of our current understanding of mammalian SCF
complexes.
2. Historical perspective
A consensus on how the cell cycle is thought to function
emerged in the late 1980s. Genetic experiments in Schizosac-
charomyces pombe (¢ssion yeast) and S. cerevisiae (budding
yeast) indicated that the eukaryotic cell cycle was de¢ned by
transitions from one state (G1/S) to another (G2/M). Cell
division cycle (Cdc) mutants were identi¢ed in yeast that
could prevent cells from replicating their DNA, while other
mutants prevented mitosis. Biochemical experiments using ex-
tracts from Xenopus laevis that accurately reproduce the cell
cycle in vitro provided an experimental system that advanced
our understanding of M phase regulation. (These data were
originally reviewed in [7,8] ; refer to [9] for a current review of
the cell cycle.)
Initially, a complex called maturation promoting factor or
M phase promoting factor (MPF) was identi¢ed and had the
ability to release Xenopus oocytes from meiotic arrest. MPF
was puri¢ed as two components, a kinase (found to be ho-
mologous to S. pombe Cdc2) and a cyclin subunit. This latter
was shown to be the regulatory subunit required for the cata-
lytic activation of Cdc2. At the time that MPF was puri¢ed,
cyclins were divided into two classes, A and B, based on their
size, kinetics of appearance in the cell cycle, and sequence
homology. The destruction of these cyclins during M phase
was responsible for the loss of kinase activity that allowed for
exit from mitosis. This was the ¢rst suggestion that selective
proteolysis played an important role in the cell cycle.
A more direct indication of the relationship between regu-
lation of the cell cycle and ubiquitin-dependent degradation
emerged from insight into the role of Cdc34 in budding yeast.
Cdc34 was known as an essential regulator of the G1/S tran-
sition. In 1988, Goebl and colleagues discovered that Cdc34
also had ubiquitin-conjugating activity. It could catalyze the
covalent attachment of ubiquitin to histones H2A and H2B in
Fig. 1. Schematic representation of the hierarchy of the ubiquitin pathway. The ubiquitin-activating enzyme (E1) transfers activated ubiquitin
to one of many ubiquitin-conjugating enzymes (E2s or Ubcs). With the help of one of many ubiquitin ligases (E3s or Ubls), an E2 transfers
ubiquitin to the substrate(s) to target it for degradation. The dashed arrows suggest the variety of combinatorial interactions between di¡erent
E2s and di¡erent E3s that are possible. The complexity and speci¢city of this pathway increases with each enzymatic reaction in the cascade.
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vitro [10]. Curiously, the signi¢cance of the in vitro ubiquitin-
conjugating activity of Cdc34 on histones remains unclear to
this day since H2A and H2B are long-lived cellular proteins.
Importantly, Cdc34 has proven fundamental to our knowl-
edge of the SCF system of ubiquitin-dependent degradation.
3. SCFcdc4 in S. cerevisiae
The classic example of SCF-dependent degradation
emerged from genetic studies in S. cerevisiae. In this yeast,
entry into S phase requires the activity of the S phase promot-
ing complex Clb5^Cdc28 (where Clb5 is an S phase kinase
and Cdc28 is an S. cerevisiae cdk). This complex is assembled
during G1 phase, but is inactive due to high levels of Sic1, a
Clb5^Cdc28 inhibitor. The loss of Cdc34, as well as Cdc4 or
Cdc53 (also cloned in screens for cell cycle mutants), each
results in a failure to initiate DNA replication despite high
levels of Cln^Cdc28 kinase activity (Clns are the G1 cyclins in
this yeast). Data from several groups explained this arrest in
G1 as the inability to eliminate Sic1. Sic1 was blocking the
activity of the downstream Clb5^Cdc28 kinase, whose activa-
tion is necessary for DNA replication [11,12]. These ¢ndings
suggested that Sic1 must be degraded in late G1 by a proteo-
lytic pathway requiring the ubiquitin-conjugating activity of
Cdc34, as well as functional Cdc4 and Cdc53 [13,14]. Further
experiments demonstrated that the Cdc34-mediated degrada-
tion of Sic1 is triggered by the phosphorylation of Sic1 by
Cln^Cdc28 [15^18].
The idea that a multiprotein complex directed Sic1 degra-
dation became apparent after the discovery that Cdc34 physi-
cally associated with Cdc53 and Cdc4 [19,20]. Additional ge-
netic experiments led to the identi¢cation of Skp1, which was
isolated as a suppressor of a Cdc4 mutant [21]. Human Skp1
had been identi¢ed as an interactor of the cyclin A/Cdk2
complex (S phase kinase interacting protein 1) but its function
was not understood [22]. Then in a screen for suppressors of
Cdc4 mutants, Harper’s and Elledge’s groups found that dif-
ferent Skp1 mutants could arrest yeast in either G1 or G2. An
alignment of Skp1-interacting proteins, including Cdc4,
Met30, Grr1, and L-Trcp, resulted in the identi¢cation of a
Skp1-interaction motif called the F-box, because it was also
found in cyclin F [21]. In addition to its function in Sic1
proteolysis, Skp1 was shown to have a role in Cln2 stability.
The degradation pathways of Sic1 and Cln2 both require the
same proteins, Cdc34, Skp1, and Cdc53. However, the F-box
protein required for Cln2 degradation is Grr1, not Cdc4
[19,23,24]. From these observations came the F-box hypoth-
esis : multiple SCF-dependent proteolytic pathways exist
where Skp1 binds to di¡erent F-box proteins, each targeting
particular substrates for degradation (Fig. 2) (reviewed in
[5,6,25]).
Finally, in 1997 two independent groups reconstituted Sic1
ubiquitination in vitro using puri¢ed components of the
SCFCdc4 ligase (Skp1, Cdc53, and Cdc4) in the presence of
ubiquitin, E1, Cdc34, and Cln/Cdc28 (this latter complex is
required to phosphorylate Sic1) [17,18]. This was the ¢rst
characterization of the speci¢c SCF ligase subunits that con-
trol the ubiquitination of a distinct substrate.
4. SCF subunits
4.1. F-box proteins
Analysis of several SCFs has revealed common structural
and functional themes. The F-box protein confers substrate
speci¢city by recruiting a particular target to the core ubiq-
uitination machinery. The hallmark of an F-box protein is a
conserved domain of approximately 40 amino acids that me-
diates binding to Skp1 and de¢nes the F-box. A family of 49
mammalian F-box proteins was identi¢ed using Skp1 as the
bait in a yeast two-hybrid screen and by searching DNA data-
bases with the conserved motif [26,27]. They were divided into
three classes based on additional protein^protein interaction
domains C-terminal to the F-box that are thought to be in-
volved in the binding of the substrate. Fbws contain WD-40
domains, Fbls contain leucine-rich repeats, and Fbxs contain
no or di¡erent motifs (Fig. 3). The gene nomenclature follows
a four-letter system of reference: FBXW, FBXL, and FBXO.
This recent identi¢cation of a large family of mammalian
F-box proteins promises a diverse pool of SCF-regulated sub-
strates involved in a range of cellular processes.
Fig. 2. Schematic representation of budding yeast SCFCdc4, SCFGrr1, and SCFMet30. These ubiquitin ligases are called SCFs because each is
formed by three major subunits: Skp1, Cdc53 (also called CulA), and one of many F-box proteins. SCF ligases also contain a small RING ¢n-
ger protein subunit called Hrt1 through which they bind to the ubiquitin-conjugating enzyme Cdc34. SCFCdc4 binds phosphorylated Sic1
through the F-box protein Cdc4 (which also targets Cdc6, Far1, and Gcn4 for degradation). SCFGrr1 binds phosphorylated Cln1 through the
F-box protein Grr1 (which also targets Cln2 and Gic1/2 for degradation). SCFMet30 binds phosphorylated Swe1 through the F-box protein
Met-30.
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Several genetic models of loss of function have been gen-
erated that implicate individual F-box proteins in the regula-
tion of embryonic development and cell proliferation. Fbxw4,
which encodes the protein Dactylin, is disrupted in the mouse
dactyplasia mutant. Normally, Dactylin is thought to target
for destruction a suppressor of limb formation to allow for
the appropriate level of cell proliferation. However, in Dacty-
lin-de¢cient mice this suppressor is not degraded and cell pro-
liferation is greatly diminished, resulting in the absence of
hands and feet or the development of malformed single digits
[28]. This Dac phenotype resembles the human autosomal
dominant split hand/foot malformation diseases. This is the
¢rst in vivo model demonstrating the importance of a mam-
malian F-box protein in vertebrate embryogenesis. Knockouts
of Slimb [29,30], the Drosophila homolog of L-Trcp (Fbw1a),
and of murine Skp2 (Fbl1) [31] have contributed signi¢cantly
to current insight into the physiological function of distinct
SCF complexes (see Sections 5.1 and 5.2).
4.2. Skp1
Skp1 is a critical sca¡old protein that binds one Fbp, on
one hand, and one cullin (i.e. Cdc53), on the other [18,32,33].
Some evidence suggests that Fbps and cullins can bind one
another in a Skp1-independent manner, however the presence
of Skp1 stabilizes the entire complex. While there are several
Skp1 family members, the mode of binding of these homologs
with the di¡erent F-box proteins and their biological signi¢-
cance are currently unknown (reviewed in [34]). The crystal
structure of Skp1 bound to the human F-box protein Skp2
was recently solved [35] and provides insight into the mecha-
nism of this interaction. Skp1 interacts with Skp2 via a dual
interface. The core interface is a superhelical arrangement of
the C-terminal region of Skp1 with residues 109^151 compris-
ing the F-box of Skp2. Each binding partner contains amino
acids that map to this core region and are highly conserved in
their respective family. Mutation of these residues results in
the disruption of binding. This suggests that the structure of
the core interface is maintained in most, if not all, combina-
tions of Skp1 and F-box protein family members. The varia-
ble interface is a large hydrophobic groove formed by two
helices of the F-box, helix 4 of Skp2, and the C-terminal
tail of Skp2. Only two residues in this second interface are
conserved in their respective family member. However, rea-
sonable evidence suggests that an analogous hydrophobic in-
terface will be maintained among interactions between other
F-box proteins and Skp1 homologs. The Skp1/Skp2 structure
is rigid so as to properly position the substrate and the inter-
acting E2 and ensure transfer of ubiquitin from the E2 to the
substrate.
Fig. 3. Schematic representation of di¡erent mammalian SCF complexes. Mammalian F-box proteins are divided into three classes based on
conserved motifs C-terminal to the F-box: Fbws (containing WD-40 repeats), Fbls (containing leucine-rich repeats), and Fbxs (containing dif-
ferent motifs or no motif). The question mark indicates the possibility that a speci¢c substrate can be targeted by more than one SCF. See text
for details.
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4.3. Cullins
Cul1 was originally identi¢ed in nematodes in a screen for
genes inhibiting hyperplasia [36] and is homologous to Cdc53
(also called CulA) in yeast. A family of four additional
Caenorhabditis elegans and six human genes were identi¢ed
in databases by searching with the Cul1 sequence. Cul1 is
the best characterized member of the family and is the only
one that interacts with Skp1 [37]. The name cullin comes from
the verb ‘to cul’ in the sense of ‘to sort’. In fact, at the time
that Cul1 was characterized in nematodes, the complexity of
the SCF system was only beginning to reveal itself. Because
cullins were similar to Cdc53, and Cdc53 was a subunit of the
SCF, Kipreos and Hedgecock [36] predicted that each cullin
was part of a distinct ligase that culled or sorted numerous
substrates for destruction.
Cul1 has three domains that mediate its association with
other components of the SCF (reviewed in [34]). The least
conserved domain among cullin members is the N-terminal
region which in Cul1 mediates its binding to Skp1. The second
and most highly conserved domain is present in the extreme
C-terminus of all cullins and mediates the attachment of a
small ubiquitin-like protein, Nedd8 (Rub1 in yeast). Covalent
modi¢cation of cullins by the Nedd8 pathway appears to en-
hance the ubiquitin-ligating activity of some SCF ligases (see
Section 4.5) (reviewed in [38]). A third domain downstream to
this Skp1-binding region is called the cullin homology (CH)
region or Cdc34/RING-H2 subunit-recruiting domain. This
domain is conserved among all cullins and binds to Roc1/
Rbx1 (Hrt1 in yeast) (see Section 4.4) ([39] and reviewed in
[4,5]). Other cullins also bind to Roc1 and form di¡erent
ligases with di¡erent speci¢city (Fig. 4). Cul-2 associates
with a complex of elongin C (a protein similar to Skp1),
and elongin B (an ubiquitin-related protein), and either the
VHL (Von Hippel Lindau) tumor suppressor protein or a
Socs (suppressor of cytokine signaling)-box-containing pro-
tein. Together, this complex is referred to as the VBC-like
ligase, in which VHL and probably Socs proteins carry out
the role of the substrate-targeting subunit performed by Fbps
in SCF complexes (reviewed in [4,5]). It is likely that other
cullins form similar complexes and that the SCF pathway is a
Fig. 4. Schematic representation of di¡erent mammalian cullin-based E3 ligases. Ubiquitin ligases can be subdivided based on the cullin sub-
unit. Cul1 forms an E3 ligase together with Roc1, Skp1 and one of many F-box proteins. Cul2 forms an E3 ligase together with Roc1, elongin
B, elongin C, and VHL or one of many Socs-box-containing subunits. APC2 (a cullin family member) and APC11 (homolog to Roc1) as well
as other APC subunits (not indicated here) form an E3 ligase with Cdc20 or Cdh1. The double question mark is because the subunit directly
bound by Cdc20 and Cdh1 is not known. The di¡erent complexes can assemble with di¡erent E2s as indicated. The question mark indicates
the possibility that a speci¢c substrate can be targeted by more than one cullin-based E3 ligase. See text for details.
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prototype system for a larger class of multi-component cullin-
based ubiquitin ligases. Interestingly, APC/C contains a cullin
subunit (Apc2) and RING ¢nger protein (Apc11) that targets
a speci¢c set of substrates.
Targeted deletion of the Cul1 gene in C. elegans and in mice
has provided useful genetic tools for the analysis of the func-
tion of this gene. In C. elegans, the loss of Cul1 results in
increased proliferation and hyperplasia in all larval tissues
examined [36]. This suggests that Cul1 is an essential negative
regulator of cell cycle. Additionally, Cul1 is required for de-
velopmentally regulated cell cycle exit (G1 to G0 transition),
however the loss of function of Cul1 in quiescent cells does
not have an e¡ect on cell cycle re-entry (G0 to G1 transition).
Mice carrying a deletion in Cul1 die around embryonic day
6.5 and cyclin E protein levels, but not mRNA are increased
in these cells (as determined by immunohistochemistry and in
situ hybridization, respectively) [40,41]. The mechanism of
developmental arrest in Cul13=3 embryos is unknown. The
accumulation of cyclin E is not likely to be the cause, since
cells have a tolerance for high levels of this cyclin [42,43]. It is
likely that the emerging role of Cul1 in SCFs is as a core
component that supports the targeting of multiple substrates,
which probably accumulate in these Cul13=3 cells. Very re-
cently, it has been reported that Cul1 is a direct transcrip-
tional target of Myc and that enforced expression of Cul1
or antisense p27 oligonucleotides is capable of overcoming
the slow growth phenotype of Myc-de¢cient mouse embryonic
¢broblasts [44]. This indicates that p27 is a major obstacle to
cell cycle progression in the absence of Cul1.
4.4. Roc1/Rbx1/Hrt1
Roc1 directly associates with Cul1 on one hand and with
Ubc3, Ubc4, or Ubc5 on the other [45,46]. However, Roc1
and the related Roc2 can bind all cullins. They both contain a
conserved C-terminal RING ¢nger (RING-H2), a cysteine-
rich fold surrounding structurally critical zinc ions. Mutation
of conserved cysteine and histidine residues in this domain
abrogates the ubiquitin ligase activity of Roc1-containing
complexes in vitro and disrupts its binding to Ubcs, but not
to Cul1 [45,46]. It has been suggested that one function of the
RING ¢nger is to stabilize the interaction between Cul1 and
Ubcs to facilitate ubiquitin transfer from the E2 to the sub-
strate [47] (reviewed in [34]). This RING ¢nger architecture is
a common structural feature of non-Hect ubiquitin ligases.
Most E3s contain a RING ¢nger that appears fundamental
to their catalytic activities. In fact, mutation in the RING
¢nger domain of the ubiquitin ligases Cbl and Mdm2 abro-
gates their ability to promote degradation (reviewed in [4]).
Interestingly, it has recently been demonstrated that the
RING domain of c-Cbl and the HECT domain of E6AP
(the ligase for the tumor suppressor p53) both recognize the
same structural elements of UbcH7 [48].
4.5. Nedd8/Rub1
Nedd8 (neural precursor cell-expressed developmentally
down-regulated) was ¢rst reported as a novel mRNA abun-
dant in fetal mouse brain [49]. Nedd8 is an 81 amino acid
protein that is 60% identical and 80% homologous to ubiqui-
tin and it is one member of an expanding class of ubiquitin-
like molecules. Both Nedd8 monomers and Nedd8 conjugated
proteins could be detected by Western blot with an antibody
speci¢c to Nedd8 [50]. Mutational analysis revealed that, like
ubiquitin, Nedd8 is also processed at its C-terminus to expose
a glycine residue essential for conjugation. The mechanism of
activation and conjugation of Nedd8 to its substrate parallels
the ubiquitin cascade. The Nedd8-activating enzyme is a het-
erodimer consisting of Uba3 that is homologous to the C-
terminal portion of E1 and APP-BP1 which is 56% similar
to the N-terminal portion of E1. It contains the critical cys-
teine residues for thioester linkage to Nedd8 [51,52]. Despite
its name, human Ubc12 does not conjugate ubiquitin but is
the Nedd8-conjugating enzyme [51^53]. All known targets of
Nedd8 conjugation in eukaryotic cells are cullin family mem-
bers. In fact, all cullins are covalently modi¢ed by the Nedd8
pathway [54] and this appears to increase the activity of some
cullin-based ligases (reviewed in [38,55]).
Loss of function of Rub1, the Nedd8 homolog in S. cere-
visiae, produces viable yeast that exhibit slow growth. Pro-
gression through the cell cycle is impaired but, clearly, Rub1
is not essential for growth in budding yeast [56]. However,
when the activity of the SCF is compromised by mutation
of Cdc34, Cdc4, Cdc53, or Skp1 in combination with deletion
of Rub1, the yeast display a lethal phenotype. This suggests
the cells are unable to modify Cdc53, as a rubylation-defective
Cdc53 displays a similar de¢cient phenotype when expressed
with mutant Cdc34.
In contrast to the slight phenotype in budding yeast, it has
recently been reported that the Nedd8 pathway is essential for
cell viability in ¢ssion yeast [57]. Forced expression of a ned-
dylation-de¢cient mutant form of Pcu1 (the Cul1 homolog)
and depletion of Nedd8 both result in defective cell growth
and the stabilization of Rum1, a cki in this yeast. Disruption
of the genes encoding the S. pombe E1 and E2 enzymes for
Nedd8 conjugation also has a lethal phenotype. These data
support the hypothesis that neddylation is a shared and crit-
ical modi¢cation for cullin-based ubiquitin ligases.
5. Mammalian SCF complexes
Thus far, two human SCF complexes have been character-
ized in great detail, SCFLÿTrcp and SCFSkp2 (Fig. 5).
5.1. SCFLÿTrcp
SCFLÿTrcp is the ¢rst mammalian ubiquitin ligase with an
assigned biological function. L-Trcp (L-transducin repeat-con-
taining protein/Fbw1a) was identi¢ed as a binding protein of
the HIV-1 viral protein, Vpu, and through this association it
participates in a novel endoplasmic reticulum-associated deg-
radation pathway that regulates CD4 proteolysis [58]. L-Trcp
was also identi¢ed along with at least six other novel human
F-box proteins in a yeast two-hybrid screen for Skp1 interac-
tors [26]. Human L-Trcp is homologous to Xenopus L-TrCp
[59], Drosophila Slimb [29], and C. elegans Lin-23 [60].
SCFLÿTrcp targets L-catenin [61^64], a proto-oncogene, and
IUBK [63,65^69] and IUBL [70], both components of the
NF-UB (nuclear factor-UB) signaling pathway, for phosphor-
ylation-dependent ubiquitination and destruction. SCFLÿTrcp
also mediates the processing of p105, another player in the
NF-UB network [71,72]. These known substrates of the
SCFLÿTrcp ligase are players in distinct cellular pathways con-
trolling proliferation or in£ammation. A L-Trcp homolog ex-
ists, called L-Trcp2, that is 78% identical and 85% homolo-
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gous to L-Trcp. It appears to target some substrates (IUB and
L-catenin) for destruction, at least in overexpression experi-
ments [73,74].
5.1.1. SCFLÿTrcp targets the NF-UB pathway. The NF-UB
network is a complex regulatory system that plays a central
role in the regulation of genes that function in in£ammation,
cell proliferation and apoptosis (reviewed in [75]). NF-UB is a
heterodimeric protein composed of a p65/RelA subunit and a
p50 subunit. It is sequestered in the cytoplasm in an inactive
form by a member of a family of inhibitory proteins, termed
IUBs, which mask its nuclear localization signal. In response
to various stimuli (i.e. viral infection or in£ammatory cyto-
kines) a signal transduction cascade is triggered, and IUBK
and IUBL [70] are phosphorylated by IKK (IUB kinase). Spe-
ci¢cally, IUBK is phosphorylated on Ser-32 and Ser-36 and
IUBL is phosphorylated on Ser-19 and Ser-23 [76^81]. These
serine residues are located in a N-terminal consensus phos-
phorylation region, DSGXXS, that is found in both proteins
and is conserved in other L-Trcp substrates. The interaction
between IUBK and L-Trcp is also dependent on an aspartic
acid residue at position 31 in the DSGXXS motif [82]. The
phosphorylated forms of IUBK and IUBL are recognized by
L-Trcp, allowing their ubiquitination and degradation. The
degradation of NF-UB inhibitory subunits liberates cytoplas-
mic NF-UB to enter the nucleus and activate the expression of
target genes. Additionally, the SCFLÿTrcp-mediated processing
of p105 to the active subunit p50 requires the phosphorylation
of the C-terminus of p105 (residues 918^934). This region
shares similar features with, but is not identical to, the
DSGXXS motif [72].
A highly conserved signaling pathway exists in Drosophila
that is analogous to that of NF-UB. Dorsoventral patterning
in early embryos is regulated by Dorsal, the NF-UB homolog.
In response to activation the IUB-like protein, Cactus, is de-
graded and Dorsal translocates to the nucleus where it acti-
vates downstream genes. Slimb-de¢cient embryos express
markedly reduced levels of these response genes [68]. There-
fore, it is likely that Slimb/L-Trcp is required for Cactus/IUB
degradation in vivo in £ies.
5.1.2. SCFLÿTrcp targets L-catenin. SCFLÿTrcp regulates
the stability of L-catenin, a downstream signaling factor in
the Wnt pathway of development and proliferation (reviewed
in [83]). In the absence of Wnt signaling, glycogen synthase
kinase 3L (GSK) induces the degradation of cytoplasmic L-
catenin via the ubiquitin-proteasome pathway. The adenoma-
tous polyposis coli (APC) tumor suppressor promotes the
binding of L-catenin to axin/conductin. Axin/conductin dra-
matically accelerates L-catenin turnover by enhancing the
phosphorylation activity of GSK [84]. GSK phosphorylates
Ser-33 and Ser-37 in the N-terminus of L-catenin. A complex
of APC, axin/conductin, and GSK is essential for L-catenin
phosphorylation. Phosphorylated L-catenin is recognized by
the F-box protein L-Trcp and through the F-box of L-Trcp,
the other subunits of the SCF complex, as well as the E2, are
recruited to L-catenin for its ubiquitination. In response to the
activation of Wnt signaling, degradation of free L-catenin de-
creases because of inactivation of GSK. Unphosphorylated L-
catenin accumulates in the cytoplasm and is then translocated
into the nucleus where it generates an active transcriptional
complex with a member of the Lef-1/Tcf-1 family of transcrip-
tion factors. Downstream targets of these transcription factors
include proto-oncogenes such as c-myc and cyclin D1 [85^87].
Fig. 5. Schematic representation of mammalian SCFLÿTrcp and SCFSkp2. SCFLÿTrcp and SCFSkp2 bind their speci¢c phosphorylated substrates,
L-catenin and p27, respectively. SCFLÿTrcp binds L-catenin through the F-box protein L-Trcp. SCFSkp2 binds p27 through the F-box protein
Skp2. SCFLÿTrcp also targets IUBK and IUBL for ubiquitin-dependent degradation. SCFSkp2 also targets free, unbound cyclin E. See text for de-
tails.
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Aberrations in this pathway can lead to deregulated growth
and oncogenesis (see below).
Genetic experiments in Drosophila provide some of the ¢rst
in vivo evidence suggesting the physiological function of
L-Trcp/Slimb. Slimb (supernumerary limbs) was initially iden-
ti¢ed in a screen for recessive mutations that alter normal
adult patterning in £ies [29,88]. The characterization of several
mutants implicated Slimb as a negative regulator of the
Hedgehog (Hh) and Wingless (Wg) signaling pathway, the
Drosophila version of the Wnt pathway. Loss of function of
Slimb results in the accumulation of Ci (Cubitus interruptus),
a transcription factor that activates the expression of Hh-re-
sponsive genes, and Armadillo (Arm), the £y homolog of L-
catenin [29]. Given the fact that Slimb is an F-box protein, it
was suggested that Slimb was part of an SCF targeting Arm
and Ci for ubiquitination and degradation.
It has recently been suggested that Slimb restricts centro-
some duplication during the cell cycle [30]. A mutant Droso-
phila line named centrosome replication-defective (crd) displays
overduplication of centrosomes and polyploidy. This is typical
of defects in mitotic progression. The crd gene is inserted into
the 5P-untranslated region of the previously identi¢ed slimb
locus. It is not clear whether Slimb is localized on centro-
somes, however, it is known that Cul1 and Skp1 are there
[89,90]. Interestingly, the Skp2 knockout in mice also exhibits
multiple centrosomes and polyploidy (see Section 5.2) [31].
Genetic mutations or altered protein expression of L-cate-
nin or APC have been implicated in human cancers. They
result in increased levels of L-catenin, which in turn lead to
increased Lef-1/Tcf-1 transcriptional activity and deregulated
proliferation [86]. An accumulation of L-catenin has been
found in several malignancies and is often the result of L-
catenin mutations that abolish the serine phosphorylation
sites required for its degradation [91]. Additionally, mutation
of Asp-32 of L-catenin (corresponding to Asp-31 in IUBK
which is essential for its association with L-Trcp) has been
detected in human cancers including synovial sarcomas
(D32Y) [92], hepatocellular carcinomas (D32N, D32Y and
D32V) [93], hepatoblastomas (D32T) [94], pilomatricomas
(D32Y and D32G) [95], and prostate cancer (D32Y) [96].
Transgenic mouse models show that L-catenin stabilization
leads to hair tumors when expressed in epidermal cells [97],
and colon adenomas when expressed in the intestines [98].
Furthermore, mice carrying an inactivating mutation in the
murine APC gene develop multiple intestinal adenomas and
are prone to develop mammary tumors [99]. Thus, both the
wild type and mutated forms of L-catenin are associated with
malignant transformation when they accumulate because of a
defect in degradation. Fluorescence in situ hybridization
(FISH) was used to map L-Trcp to chromosome position
10q24 [100]. This locus is frequently altered in tumors, how-
ever no deletions, ampli¢cations, or translocations of L-Trcp
were identi¢ed in a screen of 42 human tumor cell lines and 16
breast tumors. This lack of gross genomic alteration does not
exclude the possibility that L-Trcp is a target of genetic alter-
ation in malignancy.
5.2. SCFskp2
Skp2 (S-phase kinase-interacting protein), also called Fbl1,
is a human F-box protein that was originally discovered as an
interactor of the cyclin A/Cdk2 complex [22]. Biochemical and
somatic cell genetic experiments have implicated Skp2 in the
ubiquitin-dependent degradation of the cki p27 both in vitro
[101,102] and in vivo [101,103]. In response to mitogenic stim-
uli, p27 is phosphorylated on threonine 187 by Cdk2 [104^
106] and consequently is recognized by Skp2 [101,103].
Through the F-box of Skp2, the other subunits of the SCF
(Skp1, Cul1, and Roc1) are recruited and p27 is ubiquitinated
to be targeted for destruction. In contrast to wild type p27,
the T187A phosphorylation mutant cannot be ubiquitinated.
Moreover, immunodepletion of Skp2 from extracts abrogates
ubiquitin-conjugating activity and addition of recombinant
puri¢ed Skp2 rescues p27 ubiquitination activity. Many data
underscore the importance of Skp2 in regulating cell prolifer-
ation through its regulation of p27 degradation. Expression of
both Skp2 message [22] and protein [101,107] peaks in S phase
and then decreases as cells progress through G2 phase. Skp2
overexpression in ¢broblasts promotes progression from qui-
escence to DNA synthesis in the presence of low serum [102].
A decrease in p27 protein levels is also observed in these cells.
However, quiescent cells expressing a mutant p27 (T187A)
that cannot be phosphorylated and degraded suppress entry
into S phase. Additionally, the expression of a Skp2 F-box
mutant that cannot form a stable ligase complex is defective in
inducing S phase and cannot eliminate ectopically produced
wild type p27 [101,102]. Finally, experiments that block the
function of Skp2 in vivo through microinjection of anti-Skp2
antibodies and antisense oligonucleotides targeting Skp2
mRNA result in an inhibition of S phase entry [22] and a
stabilization of endogenous p27 [101]. These data strongly
suggest that Skp2 plays a critical role in G1 to S phase pro-
gression through its regulation of p27 proteolysis. Recently,
Skp2 has also been shown to be required for the ubiquitina-
tion of cyclin E in its free, non-Cdk2-bound form [31]. It has
been suggested that Skp2 is the F-box receptor for other cel-
lular regulators (e.g. cyclin D1, p21, Myb, and E2F-1), how-
ever limited data are currently available to support the hy-
potheses that these proteins are Skp2 substrates [31,107,108].
Skp2 is the ¢rst F-box protein whose physiological function
has been analyzed in a mouse knockout model [31]. Skp23=3
mice are smaller than their littermates, and Skp23=3 cells ex-
hibit hyper-accumulation of p27 and free cyclin E. Other cell
cycle proteins including those suggested to be Skp2 substrates
(E2F-1 and cyclin D1) are not elevated in Skp2-de¢cient cells
[31]. Mice lacking Skp2 exhibit enlarged nuclei with poly-
ploidy and multiple centrosomes. Thus, Skp2 may control
chromosome replication and centrosome duplication.
Skp2 overexpression has been observed in transformed cell
lines [22], although Skp2 overexpression, per se, is not su⁄-
cient to transform cells. Skp2 and activated Ras cooperate in
in vitro transformation assays. Additionally, studies demon-
strate that the injection of cells overexpressing Skp2 and acti-
vated Ras into nude mice induces tumors [109]. Furthermore,
it has recently been demonstrated that Skp2 cooperates with
Ras in an in vivo model of lymphogenesis [110]. The mecha-
nisms of cooperation between Skp2 and Ras to induce trans-
formation are quite complex. It is likely, however, that the
accelerated degradation of multiple Skp2 targets contributes
to the oncogenic process.
A reduction in p27 levels is necessary, but apparently not
su⁄cient in the formation of carcinomas and lymphomas.
Mice lacking p27 are larger than control animals and develop
some spontaneous tumors, speci¢cally in the pituitary [111^
113]. Furthermore, p27-de¢cient mice are susceptible to tumor
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formation in multiple tissues when challenged with carcino-
gens [114]. Numerous studies have shown that decreased levels
of p27 are of independent prognostic signi¢cance in some
cancers (reviewed in [115]). Additionally, the most aggressive
of these cancers have enhanced p27 degradation activity. It is
possible that the destabilization of p27 observed in many
types of aggressive human cancers [116^119] is due to a cor-
responding increase in the levels of Skp2 [109,110,120,121].
Thus, the inverse correlation between low expression of p27
and high levels of Skp2 may be an important prognostic in-
dicator.
6. Concluding remarks
Given the intricate temporal and spatial controls of the
ubiquitin-proteasome pathway, it is expected that aberrations
in this regulatory system are implicated in the pathogenesis of
several human diseases [1,122,123]. Mutations that a¡ect ei-
ther the enzymatic machinery of the ubiquitin pathway or the
ability of a speci¢c substrate to be targeted for destruction can
result in the dysregulation of cellular proliferation and other
biological processes. Scientists are interested in designing in-
hibitors that block the ubiquitination. Because of the wide-
ranging role of the ubiquitin pathway in many basic cellular
processes, it may be di⁄cult to limit the potentially negative
e¡ects of inhibitors that target the general ubiquitination ma-
chinery. For example, inhibitors of the proteasome are likely
to a¡ect several cellular regulatory systems non-speci¢cally. In
contrast, inhibitors of ubiquitin ligases will more speci¢cally
block distinct selected cellular processes. Ongoing e¡orts to
understand the mechanisms of speci¢city that govern this
pathway as well as the identi¢cation of new ubiquitin-protea-
some substrates promise continued discoveries that basic re-
searchers should look forward to translating to the clinic.
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